Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy for metabolic processes; electrolytes maintain fluid and electrolyte homeostasis.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion: 500 mL to 2 L per day, administered via central line at a rate not exceeding 1 mL/min for initial 30 minutes, then increase to 2 mL/min if tolerated. Dose based on patient's protein and energy requirements; typical protein equivalent: 4.25 g/100 mL.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Amino acids: variable, ~10-30 min for most; dextrose: ~1-2 h terminal half-life in healthy adults, prolonged in renal impairment.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Renal excretion of amino acids and dextrose metabolites; >90% of infused amino nitrogen is excreted renally as urea, with minimal biliary/fecal elimination.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution